viewAntisense Therapeutics Ltd

Antisense Therapeutics to commence muscular dystrophy trials

DMD affects circa one in every 3,500 to 5,000 males worldwide.

The trial is planned at the Royal Children’s Hospital in Melbourne

Antisense Therapeutics (ASX:ANP) is planning to undertake a clinical trial of its immunomodulatory therapy ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).

The trial is designed to assess the drug’s effects on the inflammation associated with this rare and incurable muscle wasting disease in children.

DMD is caused by a mutation in the muscle dystrophin gene leading to severe progressive muscle loss and premature death.

One of the most common fatal genetic disorders, DMD affects circa one in every 3,500 to 5,000 males worldwide.

A key challenge in the management of DMD patients is to reduce the inflammation that exacerbates the muscle fibre damage.

Corticosteroids are the only approved treatments for muscle inflammation, however they are not sufficiently effective and have serious side effects including adversely affecting growth rate.

As a consequence, there is an acknowledged high need for new therapeutic approaches for the treatment of inflammation associated with DMD.

Antisense’s plan to undertake a clinical trial of ATL1102 in DMD patients is facilitated by its pre-clinical and clinical experience via ATL1102’s development for the treatment of multiple sclerosis (MS).

The clinical trial of ATL1102 is planned to be undertaken at the Royal Children’s Hospital in Melbourne.

As DMD is a rare disease with a high unmet medical need, Antisense is expected to benefit materially from development incentives, including orphan drug designation that are provided to support rare disease drug development.

Antisense’s shares closed 6% higher on Monday, at $0.035.

Quick facts: Antisense Therapeutics Ltd

Price: 0.1275 AUD

Market: ASX
Market Cap: $62.35 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antisense Therapeutics Ltd named herein, including the promotion by the Company of Antisense Therapeutics Ltd in any Content on the Site, the...


Full interview: Antisense Therapeutics further develops therapeutic for...

Antisense Therapeutics Limited (ASX:ANP) managing director Mark Diamond updates Proactive on the company’s progress in developing a therapeutic for a severe disease called Duchenne Muscular Dystrophy, or DMD. The managing director spoke about the importance of the drug ATL1102 that is being...

on 4/9/19

2 min read